Central Nervous System Neoplasms
"Central Nervous System Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Descriptor ID |
D016543
|
| MeSH Number(s) |
C04.588.614.250 C10.551.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Neoplasms".
This graph shows the total number of publications written about "Central Nervous System Neoplasms" by people in this website by year, and whether "Central Nervous System Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 3 | 4 |
| 2001 | 3 | 2 | 5 |
| 2002 | 4 | 1 | 5 |
| 2003 | 4 | 1 | 5 |
| 2004 | 7 | 2 | 9 |
| 2005 | 2 | 2 | 4 |
| 2006 | 6 | 1 | 7 |
| 2007 | 8 | 1 | 9 |
| 2008 | 11 | 3 | 14 |
| 2009 | 4 | 1 | 5 |
| 2010 | 9 | 2 | 11 |
| 2011 | 11 | 1 | 12 |
| 2012 | 2 | 0 | 2 |
| 2013 | 6 | 0 | 6 |
| 2014 | 16 | 1 | 17 |
| 2015 | 6 | 0 | 6 |
| 2016 | 13 | 4 | 17 |
| 2017 | 17 | 1 | 18 |
| 2018 | 12 | 3 | 15 |
| 2019 | 13 | 3 | 16 |
| 2020 | 15 | 0 | 15 |
| 2021 | 14 | 0 | 14 |
| 2022 | 13 | 0 | 13 |
| 2023 | 16 | 0 | 16 |
| 2024 | 7 | 3 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Neoplasms" by people in Profiles.
-
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4856-4865.
-
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024 Oct; 25(10):1325-1336.
-
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors. Pediatr Blood Cancer. 2024 Oct; 71(10):e31213.
-
Immunotherapy for Solitary Fibrous Tumor (Hemangiopericytoma): A Unique Treatment Approach for a Rare Central Nervous System Tumor. Neurologist. 2024 Jul 01; 29(4):250-253.
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
-
CBTRUS Statistical Report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020. Neuro Oncol. 2024 May 06; 26(Supplement_3):iii1-iii53.
-
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors. J Neurooncol. 2024 Apr; 167(2):349-359.
-
Brain and Brain Stem Necrosis After Reirradiation for Recurrent Childhood Primary Central Nervous System Tumors: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys. 2024 Jun 01; 119(2):655-668.
-
Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024 May; 65(5):669-673.
-
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors. Pediatr Blood Cancer. 2024 Mar; 71(3):e30817.